All news

H.C. Wainwright starts Parabilis Medicines at buy

Alpha Vantage · Investing.com Canada · · AI-summarised by FinFlash

H.C. Wainwright initiated coverage on Parabilis Medicines (NASDAQ:PBLS) with a buy rating and a $40.00 price target, implying 44% upside from the $27.85 trading price. The biotechnology company develops cancer therapies on its Helicon platform, holds more cash than debt, and is not expected to be profitable this year.

Read original source

PBLS company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.